Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 0.77.

  • Protalix BioTherapeutics' Asset Utilization Ratio rose 2897.33% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year increase of 2897.33%. This contributed to the annual value of 0.68 for FY2024, which is 2757.35% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Asset Utilization Ratio of 0.77 as of Q3 2025, which was up 2897.33% from 0.81 recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Asset Utilization Ratio peaked at 0.87 during Q2 2023, and registered a low of 0.42 during Q2 2024.
  • Moreover, its 5-year median value for Asset Utilization Ratio was 0.7 (2022), whereas its average is 0.68.
  • In the last 5 years, Protalix BioTherapeutics' Asset Utilization Ratio tumbled by 5180.14% in 2024 and then surged by 9376.24% in 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Asset Utilization Ratio (Quarter) stood at 0.49 in 2021, then skyrocketed by 73.52% to 0.85 in 2022, then decreased by 10.08% to 0.76 in 2023, then increased by 3.9% to 0.79 in 2024, then dropped by 2.76% to 0.77 in 2025.
  • Its last three reported values are 0.77 in Q3 2025, 0.81 for Q2 2025, and 0.81 during Q1 2025.